Equillium (EQ) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
15 Apr, 2026Executive summary
Annual meeting scheduled for May 28, 2026, to be held virtually for stockholders of record as of April 1, 2026.
Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report on Form 10-K, are available online or by request.
Voting matters and shareholder proposals
Election of two Class II directors, Charles McDermott and Bruce D. Steel, to serve until the 2029 annual meeting.
Proposal to approve a reverse stock split at a ratio between 1-for-2 and 1-for-20, at the Board's discretion.
Ratification of Crowe LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Proposal to increase authorized common stock from 200,000,000 to 400,000,000 shares.
Provision to conduct any other business properly brought before the meeting.
Board of directors and corporate governance
Board recommends voting FOR both director nominees and all proposals listed.
Latest events from Equillium
- EQ504, a novel AhR modulator for ulcerative colitis, enters Phase I in mid-2026 after $50M financing.EQ
Cantor Global Healthcare Conference 20258 Jul 2026 - ABX464 and EQ504 modulate AhR to induce miR-124, reduce inflammation, and improve barrier function.EQ
Status update1 Jun 2026 - EQ504 targets UC with a novel, colon-specific approach, aiming for improved remission and safety.EQ
Corporate presentation14 May 2026 - Q1 2026 net loss narrowed, cash runway into 2029, Phase 1 EQ504 study set for mid-2026.EQ
Q1 202613 May 2026 - Annual meeting to vote on directors, reverse split, auditor, and share increase; Board recommends approval.EQ
Proxy filing15 Apr 2026 - 18.9M shares registered for resale after $35M private placement; pipeline targets autoimmune diseases.EQ
Registration filing7 Apr 2026 - Shareholders will vote on director elections, reverse stock split, auditor ratification, and share authorization.EQ
Proxy filing30 Mar 2026 - EQ504 targets UC with a novel, validated approach and is fully funded through key milestones.EQ
Corporate presentation30 Mar 2026 - EQ504 clinical trials set for 2026, $85M raised, cash runway into 2029, no 2025 revenue.EQ
Q4 202525 Mar 2026